2 weeks Ago By ABMN Staff
Shares of Quest Diagnostics Incorporated ( NYSE:DGX – Get Free Report ) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $164.
58. A number of equities analysts have commented on DGX shares. Citigroup increased their target price on Quest Diagnostics from $165.
00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Evercore ISI started coverage on Quest Diagnostics in a research note on Wednesday, August 28th.
They issued an “in-line” rating and a $165.00 price objective for the company. Truist Financial lifted their target price on shares of Quest Diagnostics from $158.
00 to $165.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays increased their target price on shares of Quest Diagnostics from $154.
00 to $168.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group boosted their price target on shares of Quest Diagnostics from $165.
00 to $166.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. Read Our Latest Stock Report on DGX Insiders Place Their Bets Hedge Funds Weigh In On Quest Diagnostics A number of hedge funds and other institutional investors have recently bought and sold shares of the company.
Vanguard Group Inc. lifted its position in shares of Quest Diagnostics by 2.5% during the first quarter.
Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after purchasing an additional 345,754 shares in the last quarter. Davis Selected Advisers lifted its holdings in Quest Diagnostics by 0.
4% during the 2nd quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock worth $327,257,000 after buying an additional 9,665 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Quest Diagnostics by 6.
5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock valued at $288,758,000 after buying an additional 129,395 shares during the period. DekaBank Deutsche Girozentrale grew its stake in shares of Quest Diagnostics by 2.
1% in the third quarter. DekaBank Deutsche Girozentrale now owns 748,680 shares of the medical research company’s stock worth $115,621,000 after acquiring an additional 15,047 shares in the last quarter. Finally, abrdn plc increased its position in shares of Quest Diagnostics by 3.
1% during the third quarter. abrdn plc now owns 461,887 shares of the medical research company’s stock worth $71,500,000 after acquiring an additional 13,938 shares during the period. 88.
06% of the stock is currently owned by hedge funds and other institutional investors. Quest Diagnostics Price Performance Quest Diagnostics stock opened at $160.17 on Friday.
The stock has a market capitalization of $17.88 billion, a P/E ratio of 21.75, a P/E/G ratio of 2.
75 and a beta of 0.89. The company’s fifty day moving average price is $153.
52 and its 200 day moving average price is $146.73. The company has a debt-to-equity ratio of 0.
83, a quick ratio of 1.17 and a current ratio of 1.25.
Quest Diagnostics has a 1 year low of $123.04 and a 1 year high of $162.48.
Quest Diagnostics ( NYSE:DGX – Get Free Report ) last announced its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.
26 by $0.04. Quest Diagnostics had a net margin of 8.
82% and a return on equity of 15.25%. The business had revenue of $2.
49 billion for the quarter, compared to analyst estimates of $2.43 billion. During the same quarter last year, the business earned $2.
22 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year.
As a group, equities research analysts anticipate that Quest Diagnostics will post 8.9 earnings per share for the current fiscal year. Quest Diagnostics Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 21st.
Investors of record on Friday, October 4th were given a $0.75 dividend. The ex-dividend date of this dividend was Friday, October 4th.
This represents a $3.00 annualized dividend and a yield of 1.87%.
Quest Diagnostics’s payout ratio is 40.32%. About Quest Diagnostics ( Get Free Report Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. Further Reading Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter .
.
